A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic non - squamous NSCLC with EGFR mutations and high PD-L1 expression.

NCT Number	NCT06982924
Lead Sponsor	Shanghai Chest Hospital Collaborators: Innovent Biologics (Suzhou) Co. Ltd.
Conditions	EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive
Enrollment	136 participants
Start Date	2025-06-30
Primary Completion	2026-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-21